Search Results 1501-1510 of 21895 for Inhibition
... inhibitor (ARNI), or sodium-glucose contransporter-2 (SGLT2)-inhibitors must be on stable doses for more than 4 weeks prior to screening. * Participants on ...
... inhibitors. Accessed Jan. 10, 2022. Lee MCH, et al. Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes ...
... inhibitor alone or in combination and participant must have failed therapy with an IMiD OR proteasome inhibitor; Has performance status of 0 or 1 on the ...
About this study. This is an open-label, dose-escalation study of the proviral integration site of Moloney murine leukemia virus (PIM) kinase inhibitor ...
Until recently, proton pump inhibitors (PPIs) were deemed the treatment of choice for the majority of individuals with early disease and mild to moderate ...
At least 4 weeks must have elapsed from the use of 5-alpha reductase inhibitors, estrogens, and any other anti-cancer therapy prior to randomization; At ...
... Inhibitors, Angiotensin Receptor Blockers) 2. If eGFR 25-44 ml/min/1.73m2, must have urine albumin:creatinine ratio ≥30mg/g despite maximally tolerated ...
Patients on oral thrombin inhibitors including Dabigatran and oral factor X a inhibitors such as rivaroxaban, apixaban and edoxaban, unless discontinued for ...
... inhibitors within 30 days of registration; Concurrent treatment with any medications or substances that are potent inhibitors or inducers of CYP3A4, hepatic ...
Third Annual Inhibitors to Factors VIII/IX Symposium ScholarshipThird Annual Inhibitors to Factors VIII/IX. 2016. Smartest Resident AwardWest Virginia ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!